Watch EDIT. Know when insiders buy.
One email the day a filing lands. Free.
Work order
44
WATCH · insiders 49, shorts 38
Insiders, 90 days
−$19K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $496.1MP/E —DIV YIELD —FCF YIELD -24.30%REV TTM $47M +20.8%NET INCOME −$73.9MNET CASH $124.4M52W 1.66 – 4.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $11.9M | +232.3% | — | −$18.6M | −$18.2M | — | -0.15 | −$29.6M | $106K | −$29.7M | Aug 5 |
| Q1 2026 · Mar 31 | $2.8M | −39.2% | — | −$25M | −$25M | — | -0.26 | −$23.1M | $92K | −$23.2M | Aug 5 |
| Q4 2025 · Dec 31derived | $24.7M | −19.2% | — | −$7.8M | −$5.6M | — | 0.00 | −$36.4M | $60K | −$36.4M | Mar 9 |
| Q3 2025 · Sep 30 | $7.5M | +12265.6% | — | −$24.5M | −$25.1M | — | -0.28 | −$30.8M | $433K | −$31.3M | Nov 10 |
| Q2 2025 · Jun 30 | $3.6M | +597.5% | — | −$51.5M | −$53.2M | — | -0.63 | −$50.2M | $0 | −$50.2M | Aug 5 |
| Q1 2025 · Mar 31 | $4.7M | +310.4% | — | −$76.2M | −$76.1M | — | -0.92 | −$47.8M | $114K | −$47.9M | Aug 5 |
| Q4 2024 · Dec 31derived | $30.6M | −49.0% | — | −$46.6M | −$45.4M | — | -0.55 | −$50.8M | $540K | −$51.3M | Mar 9 |
| Q3 2024 · Sep 30 | $61K | −98.9% | — | −$65.7M | −$62.1M | — | -0.75 | −$52.6M | $2.9M | −$55.5M | Nov 10 |
| Q2 2024 · Jun 30 | $513K | — | — | −$71.9M | −$67.6M | — | -0.82 | −$57.1M | $3.5M | −$60.6M | Nov 10 |
| Q1 2024 · Mar 31 | $1.1M | — | — | −$67M | −$62M | — | -0.76 | −$49.9M | $1.9M | −$51.7M | Nov 10 |
| Q4 2023 · Dec 31derived | $60M | — | — | −$24M | −$18.9M | — | -0.21 | −$22.2M | $1.3M | −$23.5M | Mar 5 |
| Q3 2023 · Sep 30 | $5.3M | — | — | −$50.2M | −$45M | — | -0.55 | −$35.5M | $239K | −$35.7M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $40.5M | — | −$160M | −$160.1M | -395.0% | -1.80 | −$165.2M | $607K | −$165.8M | — | — |
| FY2024 · to Dec 31 | $32.3M | — | −$251.2M | −$237.1M | -733.7% | -2.88 | −$210.3M | $8.8M | −$219.1M | — | — |
| FY2023 · to Dec 31 | $78.1M | — | −$169.2M | −$153.2M | -196.1% | -2.02 | −$132.2M | $4.7M | −$136.9M | — | — |
| FY2022 · to Dec 31 | $19.7M | — | −$225.9M | −$220.4M | -1118.3% | -3.21 | −$177.3M | $4.1M | −$181.5M | — | — |
| FY2021 · to Dec 31 | $25.5M | — | −$193.1M | −$192.5M | -753.6% | -2.85 | −$163.8M | $8M | −$171.8M | — | — |
| FY2020 · to Dec 31 | $90.7M | — | −$134.8M | −$116M | -127.8% | -1.98 | −$179.8M | $7.2M | −$187M | — | — |
Every number comes from Editas Medicine, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.